| A B C D E F G H I J K L M N O P Q R S T U V W X Y Z # |
Group B Streptococcus (GBS) Intra-partum, Rapid by PCR : 10843
MessageNote: RGBSIP is not indicated for late-antenatal screening for GBS colonization.Please order Perinatal Group B Streptococcus Culture (Test Code: PGBS, Interface Code: 1000724) for screening pregnant women at 35–37 weeks of gestation to determine their GBS colonization status.
Test Code
RGBSIP or 10843
Alias/See Also
Streptococcus agalactiae
CPT Codes
87653
Instructions
Vaginal/Rectal dual site swab ONLY. Collect using Red top dual Swab(Stock Item # B15089)
1. Wipe away excessive amounts of secretion or discharge.
2. Remove both swabs from the Red top dual Swab transport container.
3. Carefully insert both swabs into the patient's vagina. Sample secretions from the mucosa of the lower one-third part of the vagina. Rotate the swabs three times to ensure uniform sample on both swabs.
4. Using the same dual swabs, carefully insert both swabs approximately 2.5 cm beyond the anal sphincter, and gently rotate to sample anal crypts.
5. Place both swabs in the transport container.
1. Wipe away excessive amounts of secretion or discharge.
2. Remove both swabs from the Red top dual Swab transport container.
3. Carefully insert both swabs into the patient's vagina. Sample secretions from the mucosa of the lower one-third part of the vagina. Rotate the swabs three times to ensure uniform sample on both swabs.
4. Using the same dual swabs, carefully insert both swabs approximately 2.5 cm beyond the anal sphincter, and gently rotate to sample anal crypts.
5. Place both swabs in the transport container.
Transport Container
Submit Vaginal/Rectal Dual site swab. Refer to collection instructions.
Transport Temperature
Refrigerated.
Specimen Stability
Room temperature: 24 hours; Refrigerated: 6 days; Frozen: Unacceptable
Methodology
Qualitative real-time Polymerase Chain Reaction (PCR)
Setup Schedule
Sunday - Saturday
Report Available
1 day
Reference Range
Target Not Detected (TND)
Clinical Significance
Group B Streptococcus (GBS) infection is associated with serious illness in neonates born to women who are colonized with this bacteria. Transmission of GBS occurs from GBS-colonized women to their neonates before birth (antepartum) or during birth (intra-partum). In the United States, GBS infection is the major cause of death in neonates who develop sepsis, pneumonia, or meningitis.
Currently, the standard of care for preventing neonatal GBS disease is screening pregnant women at 35–37 weeks of gestation to determine their GBS colonization status. Most antepartum GBS testing is performed by broth enrichment followed by culture and typically takes 2-3 days to finalize results. This timing is adequate for obtaining antepartum GBS culture results for the majority of women. Universal late-antenatal screening for GBS colonization remains the cornerstone of preventing neonatal GBS disease.
However, some women may NOT have GBS results available at the onset of labor. The GBS intra-partum PCR test is an FDA approved test developed for rapid detectionof GBS directly from vaginal/rectal swab specimens. For women who have had no prenatal care, or who might deliver preterm, or whose GBS test results are unknown at the time of delivery, intra-partum testing can provide results in time to administer antibiotics before delivery, if required. In addition, a rapid negative GBS intra-partum result on the mother may help management and early discharge of the mother and neonate from the hospital.
Currently, the standard of care for preventing neonatal GBS disease is screening pregnant women at 35–37 weeks of gestation to determine their GBS colonization status. Most antepartum GBS testing is performed by broth enrichment followed by culture and typically takes 2-3 days to finalize results. This timing is adequate for obtaining antepartum GBS culture results for the majority of women. Universal late-antenatal screening for GBS colonization remains the cornerstone of preventing neonatal GBS disease.
However, some women may NOT have GBS results available at the onset of labor. The GBS intra-partum PCR test is an FDA approved test developed for rapid detectionof GBS directly from vaginal/rectal swab specimens. For women who have had no prenatal care, or who might deliver preterm, or whose GBS test results are unknown at the time of delivery, intra-partum testing can provide results in time to administer antibiotics before delivery, if required. In addition, a rapid negative GBS intra-partum result on the mother may help management and early discharge of the mother and neonate from the hospital.
Performing Laboratory
med fusion
